Cytiva Completes Renovation on Fast Trak cGMP Facility
The updated facility is 60,000 square feet and is equipped with bioprocessing capabilities ranging from 10L to 2000L.
Cytiva announced on June 24, 2020 that it has completed a renovation of its Fast Trak cGMP contract biomanufacturing and process development site in Marlborough, MA.
The updated facility is 60,000 square feet and is equipped with bioprocessing capabilities ranging from 10L to 2000, according to a company press release. The site offers technical support and single-use biomanufacturing expertise to biotechnology companies looking for assistance in bringing therapeutics to market.
“Biotechnology companies are increasingly outsourcing their manufacturing, whether to access expertise, capacity, or both,” said Olivier Loeillot, senior vice-president, BioProcess at Cytiva, in the press release. “Our upgraded Fast Trak cGMP facility will provide our customers, particularly the small to mid-size companies, with the services and expertise needed to help expedite their processes and get to market faster.”
Source: Cytiva
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
